Potential pancreatic cancer vaccine shows early success
A Phase 1 trial at Johns Hopkins tested a new vaccine called mKRAS-VAX aimed at preventing pancreatic cancer in high-risk individuals. The vaccine elicited a strong immune response in 90% of participants, was well-tolerated, and showed promising signs of reducing pancreatic cysts, which are linked to increased cancer risk. While results are preliminary, researchers see potential for cancer interception and emphasize the need for larger studies to confirm efficacy.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading